Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan;27(1):2101114.
doi: 10.2807/1560-7917.ES.2022.27.1.2101114.

Serological responses to COVID-19 Comirnaty booster vaccine, London, United Kingdom, September to December 2021

Georgina Ireland  1 , Heather Whitaker  2 , Shamez N Ladhani  1   3 , Frances Baawuah  1   4 , Sathyvani Subbarao  1 , Ezra Linley  5 , Lenesha Warrener  6 , Michelle O'Brien  4 , Corinne Whillock  1 , Oliver Martin  1 , Paul Moss  7 , Mary E Ramsay  1 , Gayatri Amirthalingam  1 , Kevin E Brown  1
Affiliations

Serological responses to COVID-19 Comirnaty booster vaccine, London, United Kingdom, September to December 2021

Georgina Ireland et al. Euro Surveill. 2022 Jan.

Abstract

Serum samples were collected pre- and post-booster vaccination with Comirnaty in 626 participants (aged ≥ 50 years) who had received two Comirnaty doses < 30 days apart, two Comirnaty doses ≥ 30 days apart or two Vaxzevria doses ≥ 30 days apart. Irrespective of primary vaccine type or schedule, spike antibody GMTs peaked 2-4 weeks after second dose, fell significantly ≤ 38 weeks later and rose above primary immunisation GMTs 2-4 weeks post-booster. Higher post-booster responses were observed with a longer interval between primary immunisation and boosting.

Keywords: Antibody; AstraZeneca, Comirnaty, Vaxzevria; COVID-19; COVID-Vaccine; Immunity; Pfizer; Spike Protein.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: MER reports that the Immunisation and Vaccine Preventable Diseases Division (UKHSA) has provided vaccine manufacturers with post-marketing surveillance reports on pneumococcal and meningococcal infection, which the companies are required to submit to the UK licensing authority in compliance with their risk management strategy. A cost-recovery charge is made for these reports. EL reports that the UKHSA Vaccine Evaluation Unit does contract research on behalf of GlaxoSmithKline, Sanofi, and Pfizer, which is outside the submitted work.

Figures

Figure
Figure
SARS-CoV-2 S antibody responses < 3 weeks before the second dose of the primary COVID-19 vaccination, after the second dose and after booster dose vaccination in previously uninfected individuals, London, United Kingdom, September–December 2021(n = 626)a
See this image and copyright information in PMC

References

    1. Andrews N, Stowe J, Kirsebom F, Gower C, Ramsay ME, Lopez Bernal J. Effectiveness of BNT162b2 (Comirnaty, Pfizer-BioNTech) COVID-19 booster vaccine against covid-19 related symptoms in England: test negative case-control study. medrxiv. 2021:2021.11.15.21266341. Preprint.
    1. Twohig KA, Nyberg T, Zaidi A, Thelwall S, Sinnathamby MA, Aliabadi S, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infect Dis. 2022;22(1):35-42. 10.1016/S1473-3099(21)00475-8 - DOI - PMC - PubMed
    1. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021;385(7):585-94. 10.1056/NEJMoa2108891 - DOI - PMC - PubMed
    1. United Kingdom Health Security Agency (UKHSA). JCVI statement regarding a COVID-19 booster vaccine programmed for winter 2021 to 2022. London: UKHSA; 15 Nov 2021. Available from: https://www.gov.uk/government/news/jcvi-issues-advice-on-covid-19-booste...
    1. United Kingdom Health Security Agency (UKHSA). The Joint Committee on Vaccination and Immunisation (JCVI). JCVI issues advice on COVID-19 booster vaccines for those aged 40 to 49 and second doses for 16 to 17 year olds. London: UKHSA; 15 Nov 2021. Available from: https://www.gov.uk/government/news/jcvi-issues-advice-on-covid-19-booste...

Publication types

Substances

LinkOut - more resources